ORIC Pharmaceuticals Inc
6.85 %
-40.58 %
Yet to be announced
Company Overview
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company's pipeline includes multiple programs targeting various mechanisms of cancer resistance. Their lead product candidate, ORIC-533, is a CD73 inhibitor being developed for multiple myeloma and other hematologic cancers.
The company is currently in the research and development phase, with no commercial products yet available on the market. Their business model focuses on discovering and developing novel therapies rather than generating immediate revenue.
Revenue Sources
PassORIC Pharmaceuticals is a pre-revenue company focused on developing cancer treatments. Based on the financial data provided, the company has not generated any revenue in the past four quarters. As the company is still in the research and development phase without any commercialized products, this criterion is not applicable at this time.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
According to the financial data provided, ORIC Pharmaceuticals reported zero interest income and zero interest expense across all four quarters analyzed. The company is pre-revenue and primarily focused on research and development activities. Given that the company is not in its mature operational phase, the interest ratio checks are not applicable at this stage of the company's development.
Operational Ethics
PassBased on review of the company's public disclosures, SEC filings, and official company communications, there is no evidence of any significant ongoing associations with entities involved in human rights violations such as the state of Israel or the Chinese Communist Party. The company's operations and research facilities are primarily based in the United States.
Comments